Abstract:10023 Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease characterized by multiple progressive tumor and non-tumor manifestations, with abnormal activating MAPK pathway. Plexiform neurofibromas (PN) presents in 20-50% of NF1 patients (pts) and may cause serious complications. Selumetinib was approved for pediatric pts with NF1-related PN in US and EU, but therapeutic options remain limited in China. FCN-159 is a highly potent selective anti-tumorigenic inhibitor of MEK1/2, potentially effective in NF1-related PN. Methods: This multi-center, open-label phase1/2 clinical trial is the first-in human study to assess safety and efficacy in pediatric pts with NF1-related PN. The primary objective was to determine the dose limiting toxicity (DLT) and recommended phase 2 dose (RP2D) in the dose escalation, followed by a dose expansion phase 2 to evaluate safety and efficacy. The starting dose in pediatric pts was determined according to the adults in the dose-escalation phase (previously published in ASCO 2022, abstract no. 3011). Here, we first present the safety and efficacy results in pediatric participants. Results: As of data cut-off (November 21, 2022), 65 pts were enrolled, 19 pts in phase 1 and 45 pts in phase 2. A dose of 4 mg/m 2 (10 pts) and 5 mg/m 2 (9 pts) were evaluated in phase 1 and no DLT was observed. Pediatric pts in the 5 mg/m 2 cohort achieved similar exposure to the 8 mg adult cohort. AUC simulation from population PK model at different BSA ranges were also similar to the adults of 8 mg. Therefore, the RP2D was determined to be 5 mg/m 2 .Treatment-emergent adverse events (TEAEs) were reported in 62 pts (95.4%). Common TEAEs (≥ 20%) were mouth ulcer (43.1%), sinus arrhythmia (36.9%), upper respiratory tract infection (35.4%), folliculitis (21.5%), paronychia (21.5%), and increased blood creatine phosphokinase (20%). 5 pts (7.7%) experienced grade ≥3 treatment-related AEs (TRAEs), including 2 pts (2/10, 10%) in the 4 mg/m 2 group and 3 pts (3/55, 5.5%) in the 5 mg/m 2 group. Grade 3 TRAEs were increased aspartate aminotransferase (1.5%), electrocardiogram QT prolongation (1.5%), folliculitis (3.1%), and dermatitis acneiform (1.5%). No grade ≥ 4 TRAEs were observed. 2 pts (3.1%) reported treatment-related serious adverse events (one case of rhabdomyolysis and dermatitis acneiform each). TEAEs led to dose interruption (26.2%), and discontinuation (1.5%). No reported TEAE led to dose reduction or death. Of the 19 pts with at least one tumor assessment data after baseline, 8 (42%) pts had partial response, 11 (57.8%) with stable disease and none with disease progression. The median DOR could not be evaluated. Conclusions: Overall, FCN-159 was well-tolerated and demonstrated promising anti-tumor activity in pediatric participants with NF1-related PN. Long-term efficacy and safety follow-up are ongoing. Clinical trial information: NCT04954001 .

Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1

Innv-12. Cutaneous Toxicities Of Mitogen-Activated Protein Kinase Inhibitors In Children And Young Adults With Neurofibromatosis-1

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus.

Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib

Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1

Innv-13. Ophthalmological Complications In Nf-1 Patients Receiving Mek Inhibitors: Md Anderson Cancer Center Experience

Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors

Malignant tumors in children with neurofibromatosis Type 1

Ctni-20. Addressing Skin Adverse Events (Aes) During Mirdametinib Treatment In Patients With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (Nf1-Pn): Guidance From A Multidisciplinary Group Of Experts On The Management Of Mek Inhibitor-Associated Skin Aes

Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma

A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.

Clinical Challenges and Therapeutic Management

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors

Abstract IA010: Novel targeted therapy approaches in NF1-MPNST

A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma

LGG-38. Dose-dependent seizure control for an NF1 patient treated via MEK-inhibition for optic pathway glioma

Cutaneous Toxicity of FDA-approved Small-Molecule Kinase Inhibitors

Pigment epithelium derived factor drives melanocyte proliferation and migration in neurofibromatosis café au lait macules

A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1